Essential Pharma’s rare disease business has signed a strategic agreement with AGC Biologics under which AGC Biologics will produce Hu1418K322A (Hu14.18), a humanized monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).
SEATTLE, WA AND COPENHAGEN, DENMARK / ACCESSWIRE / June 4, 2024 / AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced at BIO International the completion of its new manufacturing building at the AGC Biologics Copenhagen campus. The completed work doubles the site's single-use bioreactor capacity for mammalian services and allows it to produce 150 more batches of drug product each year.
AGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and Drug Product Development and Manufacturing Offering Strategic partnership provides a...
Two manufacturers are joining forces to court biopharma companies looking for service providers outside of China.
While some biopharma contract manufacturers have been able to weather a tough business environment in recent months, many others continue to struggle against financing headwinds affecting the greater biotech industry.
AGC Biologics hit with 483 for poor discrepancy investigation practices, quality control issues at Washington site
FDA Issues Form 483 to AGC Biologics
CDMO AGC Biologics is constructing a new government-funded ¥50 billion ($350.5 million) facility at its Yokohama Technical Center in Japan, which is roughly half an hour’s drive from West Tokyo.
AGC Biologics Milan Receives Special Award Mention by Confindustria for Research and Innovation
AGC Biologics Signs TCR-T Cell Services Agreement to Support Medigene’s New Cell Therapy Product